(European Society of Cardiology) A single dose of mesenchymal stem cells delivered intravenously to patients with chronic non-ischemic cardiomyopathy was not associated with significant cardiac structural or functional improvements, but did result in several clinically relevant benefits, according to results from a phase II-a randomized trial.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2bLZK77
No comments:
Post a Comment